Navigation Links
TEI Biosciences Chairman, President and CEO Yiannis Monovoukas Named Ernst & Young Entrepreneur Of The Year® 2011 New England Award Semifinalist
Date:4/20/2011

BOSTON, April 20, 2011 /PRNewswire/ -- TEI Biosciences today announced that Yiannis Monovoukas, Ph.D., M.B.A., its Chairman, President and CEO, is an Ernst & Young Entrepreneur Of The Year® 2011 New England Award semifinalist. The program recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance, and personal commitment to their businesses and communities.  Dr. Monovoukas was selected as a semifinalist by a panel of independent judges.  Award winners will be announced on 15 June 2011.

"It's a true honor to be in the company of such talented entrepreneurs, in such an innovative and dynamic part of the country.  This recognition reflects the exciting things we have accomplished at TEI, but we're even more enthusiastic about the opportunities that lie ahead," said Dr. Monovoukas.

The Ernst & Young Entrepreneur Of The Year Program celebrates its 25th anniversary this year and recognizes business leaders in more than 50 countries throughout the world.

About TEI Biosciences Inc.

A Boston-based, privately-held, leading biomedical company, TEI Biosciences has applied its expertise in regenerative medicine to develop and commercialize novel biologic devices for a broad spectrum of soft tissue repair and regeneration applications -- from dura, tendon and hernia repair to plastic and reconstructive surgery, and wound healing.

TEI sells its products directly and through partnerships with some of the world's major medical device companies.  TEI's marketed products include:

  • SurgiMend® for plastic & reconstructive surgery and abdominal wall reconstruction
  • SurgiMend® PRS for breast reconstruction
  • PriMatrix™ for skin wound management
  • PriMatrix™ Ag Antimicrobial for skin wound management
  • Durepair® for cranial dura repair (marketed by Medtronic)
  • Xenform™ for pelvic floor reconstruction (marketed by Boston Scientific)
  • TissueMend® for tendon augmentation (marketed by Stryker)

About Ernst & Young Entrepreneur Of The Year®

Ernst & Young Entrepreneur Of The Year® is the world's most prestigious business award for entrepreneurs. The award encourages entrepreneurial activity among those with potential, and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, the program celebrates those who are building and leading successful, growing, and dynamic businesses.


'/>"/>
SOURCE TEI Biosciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Magellan Biosciences Announces Agreement with Bruker to Provide Microbiology Tools to Battle Drug Resistance
2. Magellan Biosciences and Miacom Diagnostics Team Up to Enable Faster, Easier Identification of Pathogens as Part of Magellans End-to-End Suite of Microbiology Products Designed to Streamline Lab Workflow and Enable Better Treatment Decisions
3. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
4. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
5. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
6. Avantra Biosciences Offers Its Proprietary PATH® Slides for Sale
7. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
8. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
9. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
10. Swift Biosciences Presents Highly Sensitive, Highly Specific qPCR Mutation Detection Data at 18th International Molecular Medicine Tri-Conference
11. Martek Biosciences Inducted into Small Business Innovation Research (SBIR) Hall of Fame
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData Security announced ... new role of principal product architect and that ... director of customer development. Both will report directly ... officer. The moves reflect NuData,s strategic growth in ... to high customer demand and customer focus values. ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
Breaking Biology News(10 mins):